How does the Precision Peptide Genetic Test help during treatment transitions
Same class effect, mechanism is similar
After applying eligibility criteriaincluding documented weight reduction within one year prior to fertility treatment, no history of bariatric surgery or prior pregnancy, complete BMI data and no use of other anti-obesity medications (liraglutide, exenatide, dulaglutide, orlistat)eligible patients were stratified into three BMI categories: overweight (25.029.9 kg/m), obese class I (30.034.9 kg/m), and obese class IIIII ( 35.0 kg/m)
Gastroenterology 136 , 757760 (2009)
About Daiichi Sankyo Group Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose "to contribute to the enrichment of quality of life around the world." In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs
